3 TOP ASX Growth Stocks To Watch: December 2021 📈 (BRN, RAC, KGN)

TL;DR

Race Oncology, Kogan, and BrainChip are three stocks to keep an eye on in December 2021 for different reasons.

Transcript

three top stocks to watch for december 2021 time flies it feels like just yesterday we were kick-starting into 2021 hoping to leave behind what was truly a tumultuous 2020. we were looking forward to an economic recovery and hoping that we will continue to move towards that right direction it's been an action-packed year it's been driven by a range... Read More

Key Insights

• 🥰 Race Oncology's focus on fgo inhibitors and the potential of Xantrine to protect the heart present significant opportunities in the field of cancer research.
• ❓ Kogan's inventory issues and declining share price may provide buying opportunities, especially if there are renewed lockdowns due to the Omicron variant.
• 🧘 BrainChip's transition to commercialization and the development of their neuromorphic processor position them for potential growth and partnerships.
• 🤩 The healthcare, e-commerce, and semiconductor sectors are key areas to watch in December 2021.
• ↩️ The potential return of lockdowns due to the Omicron variant may impact the performance of certain stocks, such as Kogan.
• 🎁 The growth of online retail and digital sales presents opportunities for e-commerce companies like Kogan.
• 🉐 Patents and intellectual property protection provide a competitive advantage for companies like BrainChip.

Questions & Answers

Q: What is Race Oncology's focus and recent discovery?

Race Oncology is focused on cancer research, specifically in the field of fgo inhibitors. They recently discovered that their drug, Xantrine, has the potential to protect the heart when paired with other chemotherapy drugs.

Q: What challenges has Kogan faced recently?

Kogan has faced inventory issues, leading to excess inventory and lower margins. They also experienced a decline in share price. However, the potential return of lockdowns due to the Omicron variant may drive renewed interest in the company.

Q: What is BrainChip's transition from R&D to commercialization?

BrainChip has developed a neuromorphic processor called Akida and is now focusing on commercializing their product. They have been actively promoting their technology, entering into partnerships, and expanding their customer base.

Q: What are the key drivers for each of these stocks to watch?

For Race Oncology, the potential of their drug Xantrine to treat cancer and protect the heart is a key driver. For Kogan, potential lockdowns and the growth of e-commerce are important factors. For BrainChip, the transition from R&D to commercialization and the potential of their neuromorphic processor are key drivers.

Summary & Key Takeaways

• Race Oncology is a company focused on cancer research, specifically in the field of fgo inhibitors. They have made significant progress in developing a potential treatment and have recently discovered that their drug, Xantrine, has the potential to protect the heart.

• Kogan, an e-commerce company, experienced significant growth during the pandemic but has faced inventory issues and a decline in share price. However, with the potential return of lockdowns due to the Omicron variant, there may be renewed interest in pandemic winners like Kogan.

• BrainChip is transitioning from an R&D-focused company to one focused on commercialization. They have developed a neuromorphic processor called Akida and have been actively promoting their product, entering into partnerships, and expanding their reach.